AR018891A1 - Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol - Google Patents
Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosolInfo
- Publication number
- AR018891A1 AR018891A1 ARP990102934A ARP990102934A AR018891A1 AR 018891 A1 AR018891 A1 AR 018891A1 AR P990102934 A ARP990102934 A AR P990102934A AR P990102934 A ARP990102934 A AR P990102934A AR 018891 A1 AR018891 A1 AR 018891A1
- Authority
- AR
- Argentina
- Prior art keywords
- beta
- aerosol
- pressurized
- agonist drug
- agonist
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 10
- 238000005259 measurement Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 13
- 229940125388 beta agonist Drugs 0.000 abstract 9
- 229940079593 drug Drugs 0.000 abstract 9
- 239000003814 drug Substances 0.000 abstract 9
- 238000009472 formulation Methods 0.000 abstract 9
- 239000002245 particle Substances 0.000 abstract 4
- 239000003380 propellant Substances 0.000 abstract 4
- 229940071648 metered dose inhaler Drugs 0.000 abstract 3
- 238000005057 refrigeration Methods 0.000 abstract 2
- 230000003381 solubilizing effect Effects 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se provee entonces un inhalador presurizado de dosificacion medida que contenga una formulacion estable de un fármaco beta-agonista, que no requiera derefrigeracion y, además, una formulacion estable de un fármaco beta-agonista que resulte adecuada para ser utilizada en un aerosol y no requiera derefrigeracion. Un inhalador presurizado de dosificacion medida que presenta un contenedor equipado con una válvula de dosificacion y contieneuna formulacion en aerosol presurizada preparada a partir deuna composicion que comprende: un fármaco beta-agonista; al menos un propelente fluoroalcano: ymas del 5% en peso, con relacion al peso total de la formulacion en aerosol, de un disolvente capaz de solubilizar o disolver el fármaco beta-agonista.Un inhalador presurizado de dosificacion medida que presenta un contenedor equipado con una válvula de dosificacion y contiene una formulacion enaerosol presurizada preparada a partir de una composicion que comprende: partículas de un fármaco beta-agonista, al menos un propelente fluoroalcano: y unsurfactante capaz de formar una suspension de las partículas de fármaco beta-agonista. Una formulacion en aerosol adaptada para ser utilizada en un aerosolpresurizado, la cual se prepara a partir de una composicion que comprende:un fármaco beta-agonista; al menos un propelente fluoroalcano: y más del 5% enpeso, con relacion al peso total de la formulacion en aerosol, de un disolvente capaz de solubilizar o disolver el fármaco beta-agonista. Una formulacionen aerosol adaptada para ser utilizada en un aerosol presurizado, la cual se prepara a partir de una composicion que comprende: partículas de un fármacobeta-agonista; al menos un propelente fluoroalcano: y un surfactante capaz de formar una suspension de las partículas de fármaco beta-agonista. Lasformulaciones en aerosol son estables bajo condiciones de hasta 40*C y 75*C de humedad relativa durante al menos 4 semanas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/099,779 US6451285B2 (en) | 1998-06-19 | 1998-06-19 | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018891A1 true AR018891A1 (es) | 2001-12-12 |
Family
ID=22276581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102934A AR018891A1 (es) | 1998-06-19 | 1999-06-18 | Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6451285B2 (es) |
| EP (2) | EP1306082B1 (es) |
| JP (1) | JP2002518100A (es) |
| KR (1) | KR20010053025A (es) |
| CN (2) | CN1522692A (es) |
| AR (1) | AR018891A1 (es) |
| AT (2) | ATE250409T1 (es) |
| AU (1) | AU762927B2 (es) |
| BR (1) | BR9912170A (es) |
| CA (1) | CA2335303A1 (es) |
| CO (1) | CO5031245A1 (es) |
| DE (2) | DE69915144T2 (es) |
| DK (2) | DK1085856T3 (es) |
| ES (2) | ES2215153T3 (es) |
| HU (1) | HUP0102468A3 (es) |
| IL (1) | IL140340A0 (es) |
| NO (1) | NO20006466L (es) |
| PL (1) | PL345399A1 (es) |
| PT (2) | PT1306082E (es) |
| RU (1) | RU2214230C2 (es) |
| SK (1) | SK19442000A3 (es) |
| WO (1) | WO1999065460A2 (es) |
| ZA (1) | ZA200007455B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| IT1317846B1 (it) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| CN1213732C (zh) * | 2000-05-22 | 2005-08-10 | 奇斯药制品公司 | 用于加压计量吸入器的稳定药用溶液制剂 |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| US20030072717A1 (en) * | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
| US20040101483A1 (en) * | 2001-03-30 | 2004-05-27 | Rudi Muller-Walz | Medical aerosol formulations |
| EP1273292B1 (en) * | 2001-07-02 | 2004-05-26 | CHIESI FARMACEUTICI S.p.A. | Optimised formulation of tobramycin for aerosolization |
| US20030178022A1 (en) * | 2001-12-21 | 2003-09-25 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators |
| DE10205087A1 (de) * | 2002-02-07 | 2003-08-21 | Pharmatech Gmbh | Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln |
| AU2003222753B2 (en) | 2002-03-01 | 2008-04-17 | Chiesi Farmaceutici S.P.A. | Formoterol superfine formulation |
| GB0207899D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
| US20050158248A1 (en) * | 2002-08-21 | 2005-07-21 | Xian-Ming Zeng | Method of preparing dry powder inhalation compositions |
| MXPA05001903A (es) * | 2002-08-21 | 2005-04-28 | Norton Healthcare Ltd | Composicion para inhalacion. |
| GB0219511D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| US6979580B2 (en) | 2002-12-09 | 2005-12-27 | Progressant Technologies, Inc. | Process for controlling performance characteristics of a negative differential resistance (NDR) device |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| WO2007008427A2 (en) * | 2005-07-08 | 2007-01-18 | Xemplar Pharmaceuticals, Llc | Aerosol compositions and methods |
| US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| EP3106149B1 (en) * | 2009-05-29 | 2019-11-20 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| BR112015022784B1 (pt) | 2013-03-15 | 2023-02-14 | Pearl Therapeutics, Inc | Método de condicionamento de material cristalino micronizado e sistemas de condicionamento |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| EP3701940B1 (en) | 2015-12-04 | 2025-11-12 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
| ES2949975T3 (es) | 2016-09-19 | 2023-10-04 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende indacaterol |
| MX384545B (es) | 2016-09-19 | 2025-03-14 | Mexichem Fluor Sa De Cv | Composicion farmaceutica |
| AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN109464429B (zh) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | 一种吸入压力定量气雾剂药物组合物及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE556587A (es) | 1957-01-31 | 1957-04-11 | ||
| BE786200A (fr) * | 1971-07-13 | 1973-01-12 | Boehringer Sohn Ingelheim | Traitement par inhalation de maladies bronchiques |
| NL7708731A (nl) | 1976-08-13 | 1978-02-15 | Montedison Spa | Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen. |
| CA1178889A (en) * | 1980-08-28 | 1984-12-04 | Kenneth S. Su | Intranasal formulation |
| US5766573A (en) * | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| IL97065A (en) | 1990-02-02 | 1994-01-25 | Fisons Plc | Repellent preparations for aerosol |
| RU2098082C1 (ru) * | 1990-06-28 | 1997-12-10 | Глэксо Инк. | Аэрозольная лекарственная композиция для ингаляций (варианты) |
| BR9106595A (pt) | 1990-06-29 | 1993-04-20 | Fisons Plc | Composicao aerossol pressurizada |
| JP2769925B2 (ja) | 1990-10-18 | 1998-06-25 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤 |
| MX9203481A (es) | 1990-10-18 | 1992-07-01 | Minnesota Mining & Mfg | Formulaciones. |
| US5190029A (en) | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
| EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| DE4123663A1 (de) | 1991-07-17 | 1993-01-21 | Schwabe Willmar Gmbh & Co | Aerosol-zubereitung und verwendung eines treibmittels dafuer |
| NZ244439A (en) * | 1991-09-25 | 1994-01-26 | Fisons Plc | Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed |
| US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| ATE128350T1 (de) * | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
| CZ288032B6 (cs) | 1991-12-18 | 2001-04-11 | Aktiebolaget Astra | Farmaceutický prostředek pro podání inhalací |
| ES2159678T3 (es) | 1991-12-18 | 2001-10-16 | Minnesota Mining & Mfg | Formulaciones de aerosol en suspension. |
| DK0550031T3 (da) | 1991-12-31 | 1996-08-26 | Solvay | Medicinsk aerosolformulering |
| US5833950A (en) * | 1992-07-31 | 1998-11-10 | Glaxo Group Limited | Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate |
| EP0673240B1 (en) * | 1992-12-09 | 1999-03-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Stabilized medicinal aerosol solution formulations |
| US5492688A (en) | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
| US5508023A (en) | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
| JP4155594B2 (ja) | 1994-12-22 | 2008-09-24 | アストラゼネカ・アクチエボラーグ | エアゾール製剤 |
| DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| GB9616237D0 (en) * | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US6039932A (en) * | 1996-09-27 | 2000-03-21 | 3M Innovative Properties Company | Medicinal inhalation aerosol formulations containing budesonide |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| CA2273835A1 (en) | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
-
1998
- 1998-06-19 US US09/099,779 patent/US6451285B2/en not_active Expired - Fee Related
-
1999
- 1999-06-18 SK SK1944-2000A patent/SK19442000A3/sk unknown
- 1999-06-18 EP EP02026980A patent/EP1306082B1/en not_active Expired - Lifetime
- 1999-06-18 JP JP2000554340A patent/JP2002518100A/ja active Pending
- 1999-06-18 DE DE69915144T patent/DE69915144T2/de not_active Expired - Fee Related
- 1999-06-18 EP EP99931837A patent/EP1085856B1/en not_active Expired - Lifetime
- 1999-06-18 CN CNA2003101046076A patent/CN1522692A/zh active Pending
- 1999-06-18 AU AU48259/99A patent/AU762927B2/en not_active Ceased
- 1999-06-18 AT AT99931837T patent/ATE250409T1/de not_active IP Right Cessation
- 1999-06-18 PL PL99345399A patent/PL345399A1/xx unknown
- 1999-06-18 PT PT02026980T patent/PT1306082E/pt unknown
- 1999-06-18 DK DK99931837T patent/DK1085856T3/da active
- 1999-06-18 AT AT02026980T patent/ATE260093T1/de not_active IP Right Cessation
- 1999-06-18 AR ARP990102934A patent/AR018891A1/es not_active Application Discontinuation
- 1999-06-18 PT PT99931837T patent/PT1085856E/pt unknown
- 1999-06-18 KR KR1020007014438A patent/KR20010053025A/ko not_active Ceased
- 1999-06-18 DK DK02026980T patent/DK1306082T3/da active
- 1999-06-18 ES ES02026980T patent/ES2215153T3/es not_active Expired - Lifetime
- 1999-06-18 RU RU2001101889/14A patent/RU2214230C2/ru not_active IP Right Cessation
- 1999-06-18 IL IL14034099A patent/IL140340A0/xx unknown
- 1999-06-18 HU HU0102468A patent/HUP0102468A3/hu unknown
- 1999-06-18 BR BR9912170-0A patent/BR9912170A/pt not_active IP Right Cessation
- 1999-06-18 ES ES99931837T patent/ES2205848T3/es not_active Expired - Lifetime
- 1999-06-18 CA CA002335303A patent/CA2335303A1/en not_active Abandoned
- 1999-06-18 CN CNB998088641A patent/CN1154477C/zh not_active Expired - Fee Related
- 1999-06-18 WO PCT/US1999/013863 patent/WO1999065460A2/en not_active Ceased
- 1999-06-18 DE DE69911602T patent/DE69911602T2/de not_active Expired - Fee Related
- 1999-06-21 CO CO99038537A patent/CO5031245A1/es unknown
-
2000
- 2000-12-13 ZA ZA200007455A patent/ZA200007455B/en unknown
- 2000-12-18 NO NO20006466A patent/NO20006466L/no not_active Application Discontinuation
-
2002
- 2002-07-02 US US10/190,094 patent/US20030077230A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018891A1 (es) | Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol | |
| BR9916865A (pt) | Composição farmacêutica em aerossol contendohfa 227 e hfa 134a | |
| ES2199739T5 (es) | Composiciones de aerosol. | |
| US5478578A (en) | Powders for inhalation | |
| Maggi et al. | Influence of the moisture on the performance of a new dry powder inhaler | |
| AR038643A1 (es) | Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico | |
| ATE339195T1 (de) | Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets | |
| ATE128350T1 (de) | Pharmazeutische aerosolformulierung. | |
| ES2472268T3 (es) | Formulaciones de aerosol que comprenden fumarato de formoterol dihidratado, un propelente, etanol y opcionalmente un esteroide, en las que el fumarato de formoterol dihidratado tiene un contenido de agua del 4,8-4,28% en peso | |
| DE60114571D1 (de) | Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung | |
| AR009231A1 (es) | Formulaciones en aerosol de formoterol. | |
| HU208398B (en) | Process for producing pharmaceutical aerosol composition | |
| DE69227257D1 (de) | Arzneimittel | |
| ES2602314T3 (es) | Medicamento inhalable que comprende tiotropio | |
| HU226694B1 (en) | Medicinal aerosol products containing ciclesonide | |
| SE0402345L (sv) | Uppmätt läkemedelsdos | |
| US20070218011A1 (en) | Aerosol Formulation Comprising Formoterol in Suspension | |
| AR012480A1 (es) | Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona | |
| ITMI20001051A1 (it) | Formulazioni contenenti un farmaco glucocorticosteroide per il trattamento di patologie broncopolmonari | |
| CA2355651A1 (en) | Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide | |
| JP2004529108A5 (es) | ||
| FARR | The physico-chemical basis of radiolabelling metered dose inhalers with 99mTc | |
| Selvam et al. | Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics | |
| AR060039A1 (es) | Formulaciones novedosas | |
| ES2314469T3 (es) | Formulacion farmaceutica en aerosol que comprende un hidrofluoroalcano y una ciclodextrina acilada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |